Zuodong Ye

Dr. Zuodong Ye

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2022 in Advanced Science
Verified
Journal Article
Open access
ZYZuodong Ye
Zuodong Ye
YXYiding Xiong
Yiding Xiong
WPWang Peng
Wang Peng
WWWenjie Wei
Wenjie Wei
LHLihong Huang
Lihong Huang
JYJianbo Yue
Jianbo Yue
The aberrant regulation of PD‐L1 in tumor cells remains poorly understood. Here, the authors systematically investigate the endosomal trafficking of plasma membrane PD‐L1 in tumor cells. They show that plasma membrane PD‐L1 is continuously internalized, and then trafficked from early endosomes to multivesicular bodies/late endosomes, recycling endosomes, lysosomes, and/or extracellular vesicles (EVs). This constitutive endocytic trafficking of PD‐L1 is Rab5‐ and clathrin‐dependent. Triazine compound 6J1 blocks the endosomal trafficking of PD‐L1 and induces its accumulation in endocytic vesicles by activating Rab5. 6J1 also promotes exosomal PD‐L1 secretion by activating Rab27. Together, these effects result in a decrease in the membrane level of PD‐L1 in 6J1‐treated tumor cells and enables tumor cells to be more susceptible to the tumor‐killing activity of T cells in vitro. 6J1 also increases tumor‐infiltrating cytotoxic T cells and promotes chemokines secretion in the tumor microenvironment. Rab27 knockdown abolishes 6J1‐induced PD‐L1 secretion in EVs and revokes the exhausted tumor‐infiltrating T cells in tumors, thereby improving the anticancer efficacy of 6J1. Furthermore, a combination of 6J1 and an anti‐PD‐1 antibody significantly improves the anticancer immune response. Therefore, manipulating PD‐L1 endosomal trafficking provides a promising means to promote an anticancer immune response in addition to the immune checkpoint‐blocking antibody therapy.

24 April 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
LHLihong Huang
Lihong Huang
TYTerrence Tsz-Tai Yuen
Terrence Tsz-Tai Yuen
ZYZuodong Ye
Zuodong Ye
SLShuyan Liu
Shuyan Liu
GZGuoliang Zhang
Guoliang Zhang
JYJianbo Yue
Jianbo Yue

9 February 2021 in Oncogene
Verified
Journal Article
Open access
PDF file
ZYZuodong Ye
Zuodong Ye
DWDawei Wang
Dawei Wang
YLYingying Lu
Yingying Lu
YHYunjiao He
Yunjiao He
JYJingting Yu
Jingting Yu
JYJianbo Yue
Jianbo Yue
Metastasis is the fundamental cause of cancer mortality, but there are still very few anti-metastatic drugs available. Endosomal trafficking has been implicated in tumor metastasis, and we have previously found that small chemical vacuolin-1 (V1) potently inhibits autophagosome-lysosome fusion and general endosomal-lysosomal degradation. Here, we assessed the anti-metastatic activity of V1 both in vitro and in vivo. V1 significantly inhibits colony formation, migration, and invasion of various cancer cells in vitro. It also compromises the assembly-disassembly dynamics of focal adhesions (FAs) by inhibiting the recycling and degradation of integrins. In various experimental or transgenic mouse models, V1 significantly suppresses the metastasis and/or tumor growth of breast cancer or melanoma. We further identified capping protein Zβ (CapZβ) as a V1 binding protein and showed that it is required for the V1-mediated inhibition of migration and metastasis of cancer cells. Collectively, our results indicate that V1 targets CapZβ to inhibit endosomal trafficking and metastasis.

16 April 2022 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
KZKaiyuan Zhu
Kaiyuan Zhu
YCYang Cai
Yang Cai
XSXiaotong Si
Xiaotong Si
ZYZuodong Ye
Zuodong Ye
YGYuanzhu Gao
Yuanzhu Gao
JYJianbo Yue
Jianbo Yue

Verified
Journal Article
Open access
PDF file
YLYue Liu
Yue Liu
KLKa Sin LUI
Ka Sin LUI
ZYZuodong Ye
Zuodong Ye
LCLuo CHEN
Luo CHEN
Allen Ka Loon CheungAllen Ka Loon Cheung
Allen Ka Loon Cheung
Epstein–Barr virus is highly associated with nasopharyngeal carcinoma (NPC) with genes expressed for tumor transformation or maintenance of viral latency, but there are certain genes that can modulate immune molecules. Butyrophilin 2A1 (BTN2A1) is an important activating protein for presenting phosphoantigens for recognition by Vγ9Vδ2 T cells to achieve antitumor activities. We have previously shown that Vγ9Vδ2 T cells achieve efficacy against NPC when BTN2A1 and BTN3A1 are upregulated by stimulating EBV gene expression, particularly LMP1. While BTN3A1 can be induced by the LMP1-mediated IFN-γ/JNK/NLRC5 pathway, the viral gene that can regulate BTN2A1 remains elusive. We showed that BTN2A1 expression is directly mediated by EBV BRRF1, which can trigger the BTN2A1 promoter and downstream JAK3-STAT3 pathway in NPC43 cells, as shown by RNA-seq data and verified via inhibitor experiments. Furthermore, BRRF1 downregulated IL-22 binding protein (IL-22RA2) to complement the EBNA1-targeting probe (P4)-induced IL-22 expression. Therefore, this study elucidated a new mechanism of stimulating BTN2A1 expression in NPC cells via the EBV gene BRRF1. The JAK3-STAT3 pathway could act in concordance with IL-22 to enhance the expression of BTN2A1, which likely leads to increased tumor cell killing by Vγ9Vδ2 T cells for enhanced potential as immunotherapy against the cancer.

17 August 2026 in EMBO Molecular Medicine
Verified
Journal Article
Open access
ZCZhenfeng Chen
Zhenfeng Chen
YQYueying Qin
Yueying Qin
BLBingqi Lin
Bingqi Lin
LJLinle Jiang
Linle Jiang
ZFZhencheng Feng
Zhencheng Feng
YPYang Peng
Yang Peng
Although diabetic complications are well-established in multiple organs, their impact on the respiratory system remains unclear. Clinical evidence indicates accelerated chronic obstructive pulmonary disease (COPD) progression in individuals with diabetes, yet the underlying mechanisms are poorly defined. Using single-cell RNA sequencing of airway epithelium, we identified distinct transcriptional alterations in COPD patients with or without diabetes, particularly in host–defense pathways related to viral infection, which is a key driver of COPD exacerbations. Functionally, hyperglycemia enhanced influenza virus susceptibility in both COPD-derived epithelial cells and COPD mice with diabetes, indicating compromised airway defense. We further demonstrated that hyperglycemia promotes advanced glycation end products (AGEs) accumulation in airway epithelium, with AGEs levels correlating with infection severity. Pharmacological inhibition of AGEs formation with aminoguanidine significantly reduced viral load both in vitro and in vivo. Mechanistically, AGEs activate p38/ERK/IKK proinflammatory signaling via RAGE and MD2 receptors, leading to epithelial injury and heightened viral susceptibility. Our findings reveal a hyperglycemia-AGEs-RAGE/MD2 axis that increases viral susceptibility in COPD, highlighting AGEs targeting as a promising therapeutic strategy for COPD patients with diabetes.